健康与疾病状态下血浆血管性血友病因子水平的遗传调控
本文综述血浆血管性血友病因子(VWF)水平的遗传调控,指出该指标为连续分布的复杂数量性状,正常人群范围为50-200%,约65%的变异可遗传;影响VWF糖基化、分泌和清除的数量性状基因座与正常人血浆VWF抗原水平相关,并可能参与1型血管性血友病及血栓倾向患者的VWF数量异常。
要点
- 正常人群血浆VWF水平呈连续分布,范围为50-200%。
- VWF低于50%与出血风险增加相关,高于150%影响动静脉血栓栓塞风险。
- 约65%的血浆VWF水平变异可遗传,VWF基因变异仅解释其中约5%。
核心结论
- 血浆VWF水平是受多基因调控的复杂数量性状,鉴定其遗传修饰因子可能有助于1型血管性血友病的分子诊断和识别血栓风险增高的个体。
研究设计与样本
- 综述类:围绕健康与疾病状态下血浆VWF水平的遗传调控,汇总观察性性状定位研究(包括全基因组关联研究和连锁分析)及假说驱动研究的结果。
主要发现
- 血浆VWF水平在正常人群中呈连续分布,范围为50-200%;血浆VWF低于50%与出血风险增加相关,高于150%影响动脉和静脉血栓栓塞风险。
- 估计约65%的血浆VWF水平变异可遗传,VWF基因变异约解释遗传影响的5%,其他遗传位点也强烈影响血浆VWF水平。
- 影响VWF糖基化、分泌和清除的数量性状基因座与正常人血浆VWF抗原水平相关,并可能参与血栓倾向或1型血管性血友病患者的VWF数量异常。
关键数值与推荐
- 正常人群血浆VWF水平范围为50-200%;VWF低于50%与出血风险增加相关,VWF高于150%影响动脉和静脉血栓栓塞风险。
- 约65%的血浆VWF水平变异估计为可遗传;VWF基因变异约解释对血浆VWF水平遗传影响的5%。
临床怎么用
- 作者认为,鉴定血浆VWF水平的遗传修饰因子可能有助于更好地对1型血管性血友病进行分子诊断,并识别血栓风险增高的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma levels of the multimeric glycoprotein von Willebrand factor (VWF) constitute a complex quantitative trait with a continuous distribution and wide range in the normal population (50-200%). Quantitative deficiencies of VWF (< 50%) are associated with an increased risk of bleeding, whereas high plasma levels of VWF (> 150%) influence the risk of arterial and venous thromboembolism. Although environmental factors can strongly influence plasma VWF levels, it is estimated that approximately 65% of this variability is heritable. Interestingly, although variability in VWF can account for ~ 5% of the genetic influence on plasma VWF levels, other genetic loci also strongly modify plasma VWF levels. The identification of the additional sources of VWF heritability has been the focus of recent observational trait-mapping studies, including genome-wide association studies or linkage analyses, as well as hypothesis-driven research studies. Quantitative trait loci influencing VWF glycosylation, secretion and clearance have been associated with plasma VWF antigen levels in normal individuals, and may contribute to quantitative VWF abnormalities in patients with a thrombotic tendency or type 1 von Willebrand disease (VWD). The identification of genetic modifiers of plasma VWF levels may allow for better molecular diagnosis of type 1 VWD, and enable the identification of individuals at increased risk for thrombosis. Validation of trait-mapping studies with in vitro and in vivo methodologies has led to novel insights into the life cycle of VWF and the pathogenesis of quantitative VWF abnormalities.
引用
- Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost. 2018. PMID: 30246494. doi:10.1111/jth.14304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。